The study will start now and run in parallel with Recce’s Indonesian Phase 3 trial, which remains on track to commence shortly. This program does not impact the initiation timeline of the ...

This approval will allow up to 20 additional patients to access RECCE® 327 Topical Gel (R327G) under the existing open-label study protocol. R327G has attracted strong interest from investigators ...

SYDNEY, April 10, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company or Recce), a leading developer of a new class of synthetic anti-infectives, today announced a ...